Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.27)
# 2,582
Out of 4,711 analysts
48
Total ratings
45.83%
Success rate
7.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $11.01 | +90.74% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $0.61 | +1,535.86% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $0.93 | +546.34% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $56.12 | -35.85% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $12.46 | +301.28% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $40.72 | +292.93% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $14.68 | +172.48% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $44.22 | +137.45% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $46.96 | -42.50% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $90.14 | +10.94% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.22 | +2,152.25% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $0.64 | +2,734.65% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $24 | $0.42 | +5,579.13% | 2 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $0.97 | +16,394.85% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $11.01
Upside: +90.74%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $0.61
Upside: +1,535.86%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $0.93
Upside: +546.34%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $56.12
Upside: -35.85%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $12.46
Upside: +301.28%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $40.72
Upside: +292.93%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $14.68
Upside: +172.48%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $44.22
Upside: +137.45%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $46.96
Upside: -42.50%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $90.14
Upside: +10.94%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.22
Upside: +2,152.25%
Nov 5, 2019
Maintains: Buy
Price Target: $15 → $18
Current: $0.64
Upside: +2,734.65%
Aug 15, 2018
Maintains: Buy
Price Target: $22 → $24
Current: $0.42
Upside: +5,579.13%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $0.97
Upside: +16,394.85%